Literature DB >> 394510

Vaccination against virus diseases.

K R Schell.   

Abstract

One of the most important and most lasting benefits of medicine to human health and health expenditure is the controlled immunological interruption of the vicious cycle of infectious disease such as smallpox, poliomyelitis, yellow fever, measles. Smallpox, with globally more than 2.5 million cases ten years ago, is gone. The incidence of infectious diseases with available immunoprophylaxis has been reduced by 90 % over the past two decades, while the incidence of diseases without vaccine has nearly tripled. By contrast, influenza, a disease against which there have been vaccines in existence for many years, demands more deaths than any other infectious disease. Reasons for this failure of influenza immunoprophylaxis are discussed and suggested to include: indiscriminate use of available vaccines of which some types are much less antigenic than others, the disappointment that influenza virus vaccines will not protect against influenza-like illnesses caused by noninfluenza virus pathogens and the concomitant indiscriminate rejection of all influenza vaccines as being of doubtful value; superficial vaccination policies which aim at narrow populations, leaving those most likely to spread the virus the full potential to do so; the unjustified fear of side reactions following vaccination which are considerably less severe than the disease this vaccination is attempting to prevent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 394510     DOI: 10.1007/bf02083602

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  47 in total

1.  Yellow fever and other arthropod-borne viruses; a consideration of two serological surveys made in South Western Nigeria.

Authors:  F N MACNAMARA; D W HORN; J S PORTERFIELD
Journal:  Trans R Soc Trop Med Hyg       Date:  1959-03       Impact factor: 2.184

2.  Influenza: the new acquayantance.

Authors:  T FRANCIS
Journal:  Ann Intern Med       Date:  1953-08       Impact factor: 25.391

3.  Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults.

Authors:  R Dolin; T G Wise; M H Mazur; C U Tuazon; F A Ennis
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

4.  The immune response to influenza virus. 3. Changes in the avidity and specificity of early IgM and IgG antibodies.

Authors:  R G Webster
Journal:  Immunology       Date:  1968-01       Impact factor: 7.397

5.  Benefits due to immunization against measles.

Authors:  N W Axnick; S M Shavell; J J Witte
Journal:  Public Health Rep       Date:  1969-08       Impact factor: 2.792

6.  Influenza-related mortality.

Authors:  M B Gregg; D J Bregman; R J O'Brien; J D Millar
Journal:  JAMA       Date:  1978-01-09       Impact factor: 56.272

7.  Vaccines and vaccine policy: the poliomyelitis example.

Authors:  J L Melnick
Journal:  Hosp Pract       Date:  1978-01

8.  From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration: a status report on national immunization against influenza.

Authors:  J R Seal; D J Spencer; H M Meyer
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

9.  Clinical trials with a new influenza subunit vaccine in adults and children.

Authors:  C Kunz; H Hofmann; H Bachmayer; E Liehl; A J Moritz
Journal:  Dev Biol Stand       Date:  1977 Jun 1-3

10.  Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity.

Authors:  P F Wright; J Thompson; W K Vaughn; D S Folland; S H Sell; D T Karzon
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.